Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20870315 | 0.83 | GRM5 (0.48) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL14358239 | 0.83 | GRM5 (0.48) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL1825269 | 0.77 | GRM5 (0.43) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL22048899 | 0.74 | GRM5 (0.51) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL852827 | 0.74 | GRM5 (0.51) | GRM5CCR1ALDH1A1GAAMAPT | |
| SCHEMBL382392 | 0.74 | GRM5 (0.51) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL14476045 | 0.73 | GRM5 (0.39) | GRM5CCR1ALDH1A1GAAMAPT | |
| SCHEMBL30309207 | 0.72 | GRM5 (0.47) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL19859465 | 0.72 | GRM5 (0.50) | GRM5ALDH1A1GAAMAPTHSD17B10 | |
| SCHEMBL2437595 | 0.72 | NOTUM (0.43) | GRM5CCR1ALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | MERCK SHARP & DOHME CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2013003383-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243302-A1 | BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | PAICS, SBDS, SORD | GRM5 4209/4885CCR1 954/4885ALDH1A1 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.